InvestorsHub Logo
Followers 66
Posts 1221
Boards Moderated 0
Alias Born 04/02/2020

Re: None

Wednesday, 08/19/2020 2:29:19 PM

Wednesday, August 19, 2020 2:29:19 PM

Post# of 232960
Dr. Patterson was right when he described Leronlimab’s MOA as eloquent! A subcutaneous injection that can be delivered in an emergency room, an outpatient doctor’s office or even from home with a superior safety profile... Just assume all things being equal and you had several therapeutic choices with Leronlimab as one of the choices... Would doctors choose an IV drug or want a subcutaneous injection as their choice? I find it hard to believe Leronlimab wouldn’t be an overwhelming majority or unanimous choice of doctors... and, patients for that matter!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News